Review
doi: 10.1684/bdc.2010.1016.
[Phases 0, 1 and 2 oncology clinical trials: current questions]
[Article in
French]
Affiliations
- PMID: 20080458
- DOI: 10.1684/bdc.2010.1016
Item in Clipboard
Review
[Phases 0, 1 and 2 oncology clinical trials: current questions]
[Article in
French]
Bull Cancer.
2010 Jan.
Abstract
We propose here a general review of current questions related to early trials, including the choice of the primary endpoint, role of bayesian designs, role of stratification and randomization for phase 2 trials, patient selection, and new designs for phase 1 and phase 0 trials. We also discuss the difficulties to apply such methodologies to molecular targeted therapies development.
Similar articles
-
Innovation in oncology clinical trial design.Cancer Treat Rev. 2019 Mar;74:15-20. doi: 10.1016/j.ctrv.2019.01.001. Epub 2019 Jan 4. Cancer Treat Rev. 2019. PMID: 30665053 Review.
-
[Methodological approaches of clinical studies with targeted therapies].Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575. Bull Cancer. 2008. PMID: 18304903 Review. French.
-
Statistical designs for early phases of cancer clinical trials.J Biopharm Stat. 2012;22(6):1109-26. doi: 10.1080/10543406.2011.571801. J Biopharm Stat. 2012. PMID: 23075011 Review.
-
Therapeutic studies.Hematol Oncol Clin North Am. 2000 Aug;14(4):849-76, ix. doi: 10.1016/s0889-8588(05)70315-4. Hematol Oncol Clin North Am. 2000. PMID: 10949777 Review.
-
New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.Ann Hematol. 2004;83 Suppl 1:S94-6. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124692 No abstract available.
Cited by
-
Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review.PLoS One. 2017 Dec 7;12(12):e0185536. doi: 10.1371/journal.pone.0185536. eCollection 2017. PLoS One. 2017. PMID: 29216190 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
